[Omics Study of Ovarian Malignancies: From Urine Metabolomic Profile to Minimally Invasive MicroRNA Markers].

A search for efficient biomarkers of ovarian cancer is one of the current trends in gynecologic oncology. Metabolic profiling by ultra high-performance liquid chromatography and mass spectrometry (UHPLC-MS) yields information about the total set of low-molecular-weight metabolites of a patient's biological fluid sample. The metabolites may provide potential disease markers, and their combination with microRNA level data significantly increases the diagnostic value.

The metabolomic profile features of some bio logical fluids in serous ovarian adenocarcinoma patients.

Background: The search for effective biomarkers for ovarian cancer (OC) early diagnosis is an urgent task of modern oncogynecology. Metabolic profiling by ultra-high performance liquid chromatography and mass spectrometry (UHPLC-MS) provides information on the totality of all low molecular weight metabolites of patient's biological fluids sample, reflecting the processes occurring in the body. The aim of the study was to research blood plasma and urine metabolomic profile of patients with serous ovarian adenocarcinoma by UHPLC-MS.

Regulatory network of competitively interacting RNAs and effectiveness of rectal tumors radiotherapy.

Background: Currently, rectal tumors radiotherapy effectiveness reaches an acceptable level only in a small number of patients (they have a complete clinical response), which is associated with the formation of malignant cells radioresistance. A comprehensive study that integrates various epigenetic parameters would explain a number of molecular mechanisms of rectal tumor cells radioresistance and identify new bio-markers. In the last decade, using high-through-put sequencing, the competitively interacting RNAs regulatory network (long non-coding RNAs, miRNAs and mRNAs) has been shown.

Genetic and epigenetic bases of prostate tumor cell radioresistance.

Background: Radiation therapy plays a leading role in the treatment of prostate cancer, but the emergence of radioresistant forms of this disease dictates the need for a personalized ap-proach based on the data from genetic and epigenetic markers. Such markers include the copy number variation as well as gene and microRNA expression.

Purpose: The aim of the study was to validate the list of potential predictors of radioresistance of prostate tumor cells in a model experiment based on the determination of gene copy number variation, gene transcriptional activity and microRNA expression.

Genetic and epigenetic bases of prostate tumor cell radioresistance.

Background: Radiation therapy plays a leading role in the treatment of prostate cancer, but the emergence of radioresistant forms of this disease dictates the need for a personalized ap-proach based on the data from genetic and epigenetic markers. Such markers include the copy number variation as well as gene and microRNA expression.

Purpose: The aim of the study was to validate the list of potential predictors of radioresistance of prostate tumor cells in a model experiment based on the determination of gene copy number variation, gene transcriptional activity and microRNA expression.